We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VanEck ChiNext ETF (CNXT) - free report >>
ARK Genomic Revolution ETF (ARKG) - free report >>
Amplify Alternative Harvest ETF (MJ) - free report >>
Best Performing ETFs of the First Quarter
In the first quarter of 2019, US stocks posted their best quarterly performance since the financial crisis. While there are still some concerns about economic growth abroad, many now see this “bad” news as “good” news on hopes of continued monetary stimulus. In fact, dovish turns by the central banks is one of the main reasons for stocks’ strong rebound in 2019.
The US economy remains in a much better position compared with other major economies. Further, with muted inflation, the Fed is expected to refrain from raising rates. The odds of a rate cut are now higher than those for a rate hike.
The S&P 500 index rose 13% in Q1 and the Dow returned 11% but the best performer was the tech heavy Nasdaq that soared more than 16%.
The first and only US listed pure-play pot ETF--ETFMG Alternative Harvest ETF (MJ - Free Report) --soared about 46% during Q1. Its top holdings include Aurora Cannabis (ACB - Free Report) , GW Pharmaceutical and Tilray (TLRY - Free Report) .
The VanEck Vectors ChinaAMC SME-ChiNext ETF (CNXT - Free Report) offers exposure to privately owned small- and medium-sized enterprises in the “new economy” sectors in China. It was up about 38% during the quarter.
The ARK Genomic Revolution Multi-Sector ETF (ARKG - Free Report) is an actively managed ETF that provides exposure to companies in the genomics industry, including those focused on CRISPR, gene editing and targeted therapeutics. The product rose 37% during Q1.
To learn more about these ETFs, please watch the short video above.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>